LoginSignup
image de profil
Aktien Stammtisch
@Aktien_Stammtisch
4Mo·

$ABBV (-1,36 %)
AbbVie Reports Phase 2 EMPOWER Trials For Emraclidine In Schizophrenia Miss Primary Endpoint; Treatment Well-Tolerated, Further Data Analysis Underway


$BMY (-1,57 %) Bristol-Myers Squibb seems to benefits from this +13%

10
11 Commentaires
Sebastian B.@Baisse-Jumper
4Mo
Should it go down another 10%-15% at $ABBV: 🛒🛒🛒🛒
•
9
•
image de profil
Iwas M.@SSIT
4Mo
If AbbVie goes down even further, I might spontaneously get in today ^^
•
3
•
image de profil
Memo0606@Memo0606
4Mo
@SSIT swiss
think it's good for shopping
•
1
•
image de profil
Iwas M.@SSIT
4Mo
@Memo0606 I was a fool and opted for Johnson & Johnson when both values were around 140€ 😭 This value has simply burned itself into me.
•
1
•
image de profil
Memo0606@Memo0606
4Mo
@SSIT well $JNJ i think it's not bad there are just more dividends
I am also invested
•
2
•
Sebastian B.@Baisse-Jumper
4Mo
@Memo0606 Not even yet. $ABBV already has a higher dividend yield and growth is also better. Nevertheless, $JNJ is already a good share.
•
2
•
image de profil
Thomas@WolfofNersingen
4Mo
Am in
•
2
•
image de profil
Vertriebsliebhaber@Vertriebsliebhaber
4Mo
Hach, 30% at $BMY in 6 months. I can live with that 🥳😎
•
2
•
image de profil
Saschko@WarrenamBuffet
4Mo
stupid :(
••
image de profil
Stefan@Slucks87
4Mo
Gut :)
••
Proolix@Proolix
4Mo
Hm... in my overview AbbVie is shown with minus 20%. If I go to the share with minus 12% ... 🤷‍♀️ is this a known error or what is the reason for this? 🤷‍♀️
••
Participez à la conversation
S'inscrireConnexion